A Phase 2 interventional study of Hemay005 and Hemay005 in Behçet Disease, sponsored by Tianjin Hemay Pharmaceutical Co., Ltd. Terminated at 31 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-21.
Sponsored by Tianjin Hemay Pharmaceutical Co., Ltd · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Behcet Syndrome with a site in China — 7 open to participants now, 7 under way, 1 of them phase 3. Behcet Syndrome · China.
Among the 16 studies in Behcet Syndrome with a site in China, this one is the 2nd largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2020, is one of 11 in phase 2, and was the 6th registered.
136 studies on the registry are indexed under Behcet Syndrome; 42 are open to participants now.
Browse Behcet Syndrome studies →7 of the 16 studies in Behcet Syndrome with a site in China are open now. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 18–65
Peking Union Medical College Hospital · Sites in China
Ages 18–65
Ganzhou Hemay Pharmaceutical Co., Ltd · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Ages 20–65 · Healthy volunteers
Peking Union Medical College Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 28 Behcet Syndrome studies recruiting now, 7 (25%) set no upper age limit and 15 (54%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 50 across 70 interventional studies indexed under Behcet Syndrome.
Median enrollment 50 across the 13 interventional studies, 220 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 9 most frequent:
Tianjin Hemay Pharmaceutical Co., Ltd is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Tianjin Hemay Pharmaceutical Co., Ltd has 1 study filed under Behcet Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Behcet Syndrome with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06849908Peking Union Medical College HospitalBaricitinib in the Treatment of Intestinal Behçet's Syndrome | 2027-06-30 |
| NCT07833163Peking University People's HospitalCorticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym. | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Behcet Syndrome with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study with an equal randomization among the Hemay005 high dose, lower dose and placebo treatment groups. After subject randomization, each subject will enter an core-treatment Phase for 12 weeks following an extended-treatment phase for another 12weeks and a follow up phase for 4weeks.
this study is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group study to evaluate Hemay005 efficacy and safety of the treatment of patients with Behçet Disease(BD). Around 252 subjects will be randomized into this study.
The whole study will including 4 phases that a screening phase, core-treatment phase(12weeks), extended-treatment phase (12weeks) and follow-up phase(4 weeks).
Screening: All subjects will undergo a screening period of up to 6 weeks prior to baseline visit (visit 2, day of randomization, Day0).
Core treatment phase: eligible BD patients will randomly assigned to Hemay005 high-dose group, Hemay005 low-dose group, placebo (core treatment phase) + Hemay005 high-dose group (extended treatment phase), or placebo (core treatment phase) + Hemay005 low-dose group (extended treatment phase). During the core-treatment period, hemay005 will be administered twice daily for 12 weeks. The randomization was stratified to minimize the imbalance between treatment groups.
Extended treatment phase: Subjects in the high-dose and low-dose groups during the extended treatment period will still given the dose of core-treatment phase for 12 weeks. Subjects who received placebo during the core treatment will assigned to either a high-dose group or a low-dose group according the allocation at visit 2 until 12 weeks after. During this period, the subject and investigator are remain blind at this stage.
Follow up phase: Subjects in the study (also including those who withdraw from treatment for any reason) will have another follow up for 4 weeks after the end of the last administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
4.Subjects must have at least 2 oral ulcers at V1, and:
Exclusion Criteria:
1.subject has the BD related major organ activity lesions requiring therapy- pulmonary, vascular, gastrointestinal, and central nervous systems (eg, meningoencephalitis) manifestations, etc. However:
subjects who current receiving immunotherapy including:
At least 5 terminal half-lives for all biologics, including,within:
5.Laboratory examination of V1 in screening period:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Core-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg twice daily for 12 weeks.
Drug: Hemay005
In Core-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 45mg twice daily for 12 weeks.
Drug: Hemay005
In Core-treatment period, subject will take placebo for 12 weeks, and in the following extend-treatment period, subject will take Hemay005 60mg or hemay005 45mg twice daily according to pre-allocation at randomization visit for 12 weeks.
Drug: Hemay005 · Other: Placebo
to evaluate the efficacy of Hemay005 in the treatment of Behçet's disease.
Area under the curve (AUC) for the number of oral ulcers from baseline through Week 12
Time frame: week 12
Proportion of subjects achieving an oral ulcer complete response
Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) by Week 6 after dosing, and who remain oral ulcer free for at least 6 additional weeks during the Treatment Phase
Time frame: week 6
Complete response rate for oral ulcers
Complete response rate for oral ulcers at day 3, day 7 and Week 12
Time frame: day 3, day 7 and week12
change of the pain evaluation of oral ulcers as measured by Visual analogue scale(VAS)(From 0-100, the higher score means the worse outcome)
Change from baseline in the pain of oral ulcers as measured by VAS at Week 12
Time frame: week12
change of the number of oral ulcers
Change from baseline in the number of oral ulcers at Week 12
Time frame: week12
Time to oral ulcer resolution
Time to oral ulcer resolution (complete response) that the first instance when a subject has a complete response during the core-Treatment Phase
Time frame: week12
Proportion of subjects achieving an oral ulcer complete response in the core-treatment phase
Proportion of subjects achieving an oral ulcer complete response (oral ulcer-free) and who remain oral ulcer free during the core-treatment Phase
Time frame: week12
Number of oral ulcers who has a reappearance during the core-treatment phase
Number of oral ulcers following loss of complete response that the first instance when a subject has a reappearance of oral ulcers following a complete response during the core-Treatment Phase
Time frame: week12
Time to oral ulcer reappearance during the core-treatment
Time to recurrence of oral ulcers following loss of complete response that the first instance when a subject has a reappearance of oral ulcers following a complete response during the core-Treatment Phase
Time frame: week12
change of the total score of Physician's Global Assessment(PGA)
change from baseline in the total score of the PGA of skin lesions of BD at week 12 in those subjects who had at baseline
Time frame: week12
change of BD Current Activity Form(BDCAF)
change from baseline in the total score of the BDCAF questionnaire at week 12
Time frame: week12
change of Multi-Dimensional Health Assessment Questionnaire (MDHAQ)
change from baseline in the total score of the MDHAQ questionnaire at week 12
Time frame: week12
change of short from health survey(SF-36)
change from baseline in the total score of the SF-36 questionnaire at week 12
Time frame: week12
Complete response rate for genital ulcers
Complete response rate for genital ulcers at Week 12 for subjects who had genital ulcers at Baseline
Time frame: week12
change of the pain evaluation of genital ulcers
Change from baseline in the pain of genital ulcers as measured by VAS at Week 12
Time frame: week12
Change of the Behçet's syndrome activity score(BSAS) score
Change from Baseline in BSAS score at Week 12
Time frame: week12
Maximum Plasma Concentration (Cmax)
the population pharmacokinetic (popPK) characteristics Cmax of Hemay005 in BD patients
Time frame: week24
Minimum Plasma Concentration (Cmin)
the population pharmacokinetic (popPK) characteristics Cmin of Hemay005 in BD patients
Time frame: week24
Time to peak (Tmax)
the population pharmacokinetic (popPK) characteristics Tmax of Hemay005 in BD patients
Time frame: week24
Elimination half-life (T1/2)
the population pharmacokinetic (popPK) characteristics T1/2 of Hemay005 in BD patients
Time frame: week24
Area under drug time curve (AUC)
the population pharmacokinetic (popPK) characteristics AUC of Hemay005 in BD patients
Time frame: week24
Clearance (Cl)
the population pharmacokinetic (popPK) characteristics Cl of Hemay005 in BD patients
Time frame: week24
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])
the Incidence of Treatment-Emergent Adverse Events of Hemay005 in BD patients with different dosing group
Time frame: week24
the number of subjects who terminated hemay005 prematurely due to adverse events (AE) [Safety and Tolerability])
the number of subjects who terminated hemay005 prematurely due to adverse events (AE) in BD patients with different dosing group
Time frame: week24
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2020 to primary completion in Apr 2022, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hemay005
Tianjin Hemay Pharmaceutical Co., Ltd